LONDON — In the booming field of weight loss drugs, Roche has been riding high in recent months, with back-to-back positive studies of two experimental medicines that sent the company’s shares up — and those of its rivals down.
But on Thursday, company executives faced an onslaught of questions from analysts during an earnings presentation about what could come next for the company’s weight loss drugs and how they would stand apart in the wildly competitive field. Analysts asked what made the Roche drug candidates different, and how the company saw its lane given that it’s years behind other drugmakers, some of which already have products on the market.
“It’s going to be a huge market,” said Roche CEO Thomas Schinecker, seemingly trying to reassure analysts that there would be plenty of demand for the company’s drugs.
